Breast Cancer Research and Treatment

, Volume 54, Issue 1, pp 59–64 | Cite as

Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma

  • Jeffrey K. Griffith
  • Jennifer E. Bryant
  • Colleen A. Fordyce
  • Frank D. Gilliland
  • Nancy E. Joste
  • Robert K. Moyzis
Article

Abstract

Telomere shortening leads to genomic instability and has been correlated with poor outcome in several types of cancer. A recently described, robust titration assay was used to quantify telomere DNA content in frozen and paraffin-embedded specimens of 49 invasive human breast carcinomas, including tumors with normal or abnormal contents of genomic DNA, which produced regional, distant, or local disease. Telomere DNA contents ranged from 53% to 370% of the content in a reference DNA purified from normal placenta. Tumors were divided into three groups of approximately equal size based on increasing telomere DNA content. All of 16 tumors in the group with the least telomere DNA (Group I), were aneuploid compared to 9/17 tumors in the group with the most telomere DNA (Group III). The Chi-square test for trend indicated that tumors with the least telomere DNA were significantly more likely to be aneuploid than tumors with the most telomere DNA (p<0.002). Twelve of 14 tumors in Group I also produced metastatic disease compared to 8/15 tumors in Group III. The Fischer Exact Test indicated that tumors with the least telomere DNA were significantly more likely to be metastatic than tumors with the most telomere DNA (p<0.05). There was no association between telomere DNA content and patients’ age, tumors’ size, grade, stage, or fraction of cells in S-phase. The correlation of reduced telomere DNA content with aneuploidy and metastasis, both of which are associated with poor outcome in invasive breast carcinoma, implies that telomere DNA content also could have prognostic value.

aneuploidy breast cancer genomic instability metastasis prognostic markers telomeres 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Usmani BA: Genomic instability and metastatic progression. Pathobiology 61: 109–116, 1993Google Scholar
  2. 2.
    Furlong JW: DNA analysis of breast, lung, central nervous system, endocrine, and head and neck tumors. In: Keran DF, Henson CA, Hurtubise PE (eds) Flow Cytometry and Clinical Diagnosis, American Society of Clinical Pathology Press, Chicago, 1994, pp 541–595Google Scholar
  3. 3.
    Dressler LG, Seamer LC, Owens MA, Clark GN, McGuire WL: DNA flow cytometry and prognostic factors in frozen breast cancer specimens. Cancer Res 47: 5294–5302, 1987Google Scholar
  4. 4.
    Ishikawa F: Telomere crisis, the driving force in cancer cell evolution. Biochem Biophys Res Com 230: 1–6, 1997Google Scholar
  5. 5.
    Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 85: 6622–6626, 1988Google Scholar
  6. 6.
    Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB: Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 89: 10114–10118, 1992Google Scholar
  7. 7.
    Allsopp RC, Chang E, Kashefiaazam M, Rogaev EI, Piatyszek MA, Shay JW, Harley CB: Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 220: 194–200, 1995Google Scholar
  8. 8.
    Harley CB, Futcher AB, Greider CW: Telomeres shorten during aging of human fibroblasts. Nature 345: 458–460, 1990Google Scholar
  9. 9.
    Counter CM, Avillon AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921–1929, 1992Google Scholar
  10. 10.
    Hastie ND, Dempster M, Dunlop MG, Thompson EM, Green DK, Allshire RC: Telomere reduction in human colorectal carcinoma and with aging. Nature 346: 866–868, 1990Google Scholar
  11. 11.
    Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM: Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 91: 9857–9860, 1994Google Scholar
  12. 12.
    de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM, Varmus HE: Structure and variability of human chromosome ends. Mol Cell Biol 10: 518–527, 1990Google Scholar
  13. 13.
    Schmitt H, Blin N, Zankl H, Scherthan H: Telomere length variation in normal and malignant human tissues. Genes Chrom Cancer 11: 171–177, 1994Google Scholar
  14. 14.
    Parkinson EK: Do telomerase antagonists represent a novel anti-cancer strategy? Br J Cancer 73: 1–4, 1996Google Scholar
  15. 15.
    McClintock B: The stability of broken ends of chromosomes in Zea mays. Genetics 26: 234–282, 1941Google Scholar
  16. 16.
    McClintock B: The fusion of broken ends of chromosomes following nuclear fusion. Proc Natl Acad Sci USA 28: 458–463, 1942Google Scholar
  17. 17.
    Takauchi K, Tashiro S, Ohtaki M, Kamada N: Telomere reduction of specific chromosome translocation in acute myelocytic leukemia. Jap J Cancer Res 85: 127–130, 1994Google Scholar
  18. 18.
    Hiyama K, Ishioka S, Shirotani Y, Inai K, Hiyama E, Murakami I, Isobe T, Inamizu T, Yamakido M: Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene 10: 937–944, 1995Google Scholar
  19. 19.
    Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y: Length of telomere repeats in neuroblastoma: correlation with prognosis and biological characteristics. Jpn J Cancer Res 83: 159–164, 1992Google Scholar
  20. 20.
    Odagiri E, Kanda N, Jibiki K, Demura R, Aikawa E, Demura H: Reduction of telomeric length and c-erb2 gene amplification in human breast cancer, fibroadenoma and gynecomastia. Cancer 73: 2978–2984, 1993Google Scholar
  21. 21.
    Ohyashiki J, Ohyashiki K, Fujimura K, Kawakubo K, Shimamoto T, Iwabuchi A, Toyama K: Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 54: 3557–3560, 1994Google Scholar
  22. 22.
    Smith J, Yeh G: Telomere reduction in endometrial carcinoma. Am J Obstet Gynecol 167: 1883–1887, 1992Google Scholar
  23. 23.
    Dahse R, Fiedler W, Ernst G: Telomeres and telomerase: Biological and clinical importance. Clin Chem 43: 708–714, 1997Google Scholar
  24. 24.
    Bryant J, Hutchings K, Moyzis R, Griffith JK: A sensitive measure of telomere DNA content in human tissues. Biotechniques 23: 476–484, 1997Google Scholar
  25. 25.
    Dressler LG, Seamer LC: Controls, standards and histogram interpretation in DNA flow cytometry. Meth Cell Biol 41: 241–262, 1994Google Scholar
  26. 26.
    Ohyashiki K, Ohyashiki JH, Fujimura T, Kawakubo K, Shimamoto T, Saito M, Nakazawa S, Toyama K: Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Genet Cytogen 78: 64–67, 1994Google Scholar
  27. 27.
    Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar A, Hiyama K, Mieczyslaw A, Piatyszek A, Shay J: Telomerase activity in human breast cancer. J Natl Cancer Inst 88: 116–122, 1996Google Scholar
  28. 28.
    Rogalla P, Rohen C, Bonk U, Bullerdieck J: Telomere repeat fragment lengths are not correlated with histological grade in 85 breast cancers. Cancer Letters 106: 155–161, 1996Google Scholar
  29. 29.
    Zhuang Z, Bertheau P, Emmert-Buck M, Liotta L, Gnarra J, Linehan M, Lubensky I: A microdissection technique for archivalDNAanalysis of specific cell populations in lesions 1mm in size. Am J Path 146: 620–625, 1995Google Scholar
  30. 30.
    Zhuang Z, Merino M, Chuaqui R, Liotta L, Emmert-Buck M: Identical allelic loss on chromosome 11q13 in microdissected in situ invasive human breast cancer. Cancer Res 55: 467–471, 1995Google Scholar
  31. 31.
    Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: 1. The value of histological grade in breast cancer; experience from a large study with long term follow-up. Histopath 19: 403–410, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Jeffrey K. Griffith
    • 1
  • Jennifer E. Bryant
    • 1
  • Colleen A. Fordyce
    • 1
  • Frank D. Gilliland
    • 2
  • Nancy E. Joste
    • 3
  • Robert K. Moyzis
    • 4
  1. 1.Department of Biochemistry and Molecular BiologyUniversity of New Mexico School of MedicineAlbuquerqueUSA
  2. 2.Department of MedicineUniversity of New Mexico School of MedicineAlbuquerqueUSA
  3. 3.Department of PathologyUniversity of New Mexico School of MedicineAlbuquerqueUSA
  4. 4.Center for Human Genome StudiesLos Alamos National LaboratoryLos AlamosUSA

Personalised recommendations